Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Tesamorelin

Egrifta, TH9507

A synthetic growth hormone-releasing hormone analog used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy.

Quick Stats
Studies 64
Trials 24
Formula C221H366N72O67S
Clear All
Utility 3
pubmed May 12, 2025

Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study.

Mihalache. Andrew A; Volfson. Emily E; Huang. Ryan R; Zuo. Kevin K; Persitz. Jonathan J

A big database of drug side‑effects shows that people taking tesamorelin report carpal tunnel syndrome (CTS) far more often than expected – about 20 times higher than the average drug. For DIY health enthusiasts using tesamorelin to boost growth‑hormone effects, this means you should watch out for hand numbness, tingling, or wrist pain.

Utility 3
pubmed May 28, 2011

Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.

Dhillon. Sohita S

Tesamorelin is a synthetic hormone that boosts your own growth hormone release. In two solid 26‑week studies with HIV patients who have excess belly fat, it cut deep (visceral) fat and waist size, but didn’t really change the skin‑under‑the‑fat layer. The fat loss stuck around as long as you kept taking the drug, but came back when you stopped. Side effects were mild and serious problems were rare (<4%).

Utility 3
pubmed Jun 19, 2011

Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.

Stanley. Takara L TL; Falutz. Julian J; Mamputu. Jean-Claude JC; Soulban. Graziella G; Potvin. Diane...

In HIV patients with a lot of belly fat, a daily injection of tesamorelin for six months lowered visceral fat and slightly improved blood markers linked to inflammation and clot breakdown, especially adiponectin. The changes were modest and the study says more research is needed to know if these benefits matter for health.

Utility 3
pubmed Aug 16, 2021

Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease.

Stanley. Takara L TL; Fourman. Lindsay T LT; Wong. Lai Ping LP; Sadreyev. Ruslan R; Billingsley. Jam...

In a 12‑month trial, the growth‑hormone‑releasing hormone drug tesamorelin lowered several blood proteins that signal T‑cell and monocyte activity, indicating reduced immune activation. The effect was seen in people with HIV and fatty liver disease, and liver tissue also showed fewer inflammatory signals.

Utility 3
pubmed Jul 1, 2013

Growth hormone-releasing hormone effects on brain &#x3b3;-aminobutyric acid levels in mild cognitive impairment and healthy aging.

Friedman. Seth D SD; Baker. Laura D LD; Borson. Soo S; Jensen. J Eric JE; Barsness. Suzanne M SM; Cr...

A 20‑week study gave healthy older adults and people with mild cognitive problems a daily 1 mg injection of tesamorelin, a synthetic growth‑hormone‑releasing hormone. The drug raised brain GABA (an inhibitory neurotransmitter) and NAAG, lowered a brain molecule linked to Alzheimer’s (myo‑inositol), and modestly improved memory test scores. These brain chemistry changes were seen in both groups and were linked to higher IGF‑1 levels, but the study was small and the cognitive boost was modest.

Utility 3
pubmed Jul 10, 2011

Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy.

Bedimo. Roger R

Tesamorelin, a drug that mimics the hormone that tells your body to release growth hormone, has been shown in clinical trials to shrink the belly‑fat that often builds up in people with HIV who are on strong antiretroviral meds. It works, but the effect fades after you stop taking it, and we still don’t know if it lowers heart‑disease risk.

Utility 3
pubmed Jul 23, 2014

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.

Stanley. Takara L TL; Feldpausch. Meghan N MN; Oh. Jinhee J; Branch. Karen L KL; Lee. Hang H; Torria...

In a 6‑month trial, HIV patients who got daily injections of tesamorelin lost a noticeable amount of belly fat and had a small drop in liver fat, while their blood sugar only rose briefly early on and then returned to normal.

Utility 3
pubmed May 18, 2021

Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach.

Fourman. Lindsay T LT; Stanley. Takara L TL; Billingsley. James M JM; Sui. Shannan J Ho SJH; Feldpau...

In people with HIV who have fatty liver disease, the drug tesamorelin lowered liver fat and slowed scarring. It did this by cutting down blood levels of three proteins (VEGFA, TGFB1, and CSF1) that drive blood vessel growth, inflammation, and fibrosis. The bigger the drop in these proteins, the more the liver disease improved.

Utility 3
pubmed Apr 10, 2012

Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.

Stanley. Takara L TL; Falutz. Julian J; Marsolais. Christian C; Morin. Jos&#xe9;e J; Soulban. Grazie...

In people with HIV, the drug tesamorelin shrank belly fat (visceral fat) by at least 8% and, in those who responded, also lowered triglycerides, raised good‑fat hormone adiponectin, and kept blood sugar more stable over a year. The metabolic improvements tracked with how much belly fat was lost.

Utility 2
pubmed Jun 2, 2025

Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.

Ellis. Ronald J RJ; Vaida. Florin F; Hu. Keren K; Dube. Michael M; Henry. Brook B; Chow. Felicia F;...

In a small 6‑month trial, the peptide tesamorelin helped people with HIV and belly fat lose a few centimeters around the waist, but it didn’t show a clear improvement in brain function compared to standard care. The study was short, had few participants, and lacked a placebo, so the cognitive benefit remains uncertain.

Utility 2
pubmed Feb 25, 2019

Comparison of visceral fat measurement by dual-energy X-ray absorptiometry to computed tomography in HIV and non-HIV.

Fourman. Lindsay T LT; Kileel. Emma M EM; Hubbard. Jane J; Holmes. Tara T; Anderson. Ellen J EJ; Loo...

The study shows that the DXA scan, a common body‑composition tool, tends to miss a lot of the belly‑fat that a CT scan sees, especially in people (especially men) with a lot of visceral fat. It also doesn’t track changes in that fat very well over time, so if you’re using DXA to see if tesamorelin is working, you might be fooled.

Utility 2
pubmed Mar 1, 2015

Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.

Gonz&#xe1;lez-Sales. Mario M; Barri&#xe8;re. Olivier O; Tremblay. Pierre Olivier PO; Nekka. Fahima F...

This study mapped how tesamorelin, a growth‑hormone‑releasing peptide, behaves in the body of both HIV‑positive patients and healthy volunteers. It found the drug follows a simple one‑compartment model with mixed (first‑ and zero‑order) absorption and linear clearance, and that typical body size, age, race, or disease status don’t change its pharmacokinetics. The only notable change was a modest (~13%) increase in the fraction absorbed by the first‑order route after two weeks of daily dosing.

Utility 2
pubmed May 9, 2013

Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS.

Jain. Shobhit S; Desai. Ninad N; Bhangoo. Amrit A

In people with HIV, especially those on strong anti‑retroviral drugs, the body’s growth‑hormone system gets messed up, leading to fat redistribution, inflammation, and insulin problems. This can lower natural GH levels, while severe AIDS can cause high GH but low IGF‑1, showing resistance. Tesamorelin, a synthetic GHRH analog, is the only FDA‑approved drug that can shrink excess belly fat in HIV‑related lipodystrophy, but we still need more long‑term safety and effectiveness data.

Utility 2
pubmed Sep 22, 2021

Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease.

Fraile. Julia M JM; Palliyil. Soumya S; Barelle. Caroline C; Porter. Andrew J AJ; Kovaleva. Marina M

This review talks about the huge need for drugs to treat NASH, a liver disease, and lists many compounds in the pipeline. Tesamorelin, a peptide, is mentioned as one of the drugs that is expected to start Phase 3 trials soon, but there are no results yet. So right now there’s nothing concrete you can do with tesamorelin for NASH, but it’s a candidate to watch.

Utility 2
pubmed Jun 15, 2021

Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease.

Fourman. Lindsay T LT; Stanley. Takara L TL; Zheng. Isabel I; Pan. Chelsea S CS; Feldpausch. Meghan...

In a study of people with HIV and fatty liver disease, almost half already had liver scarring, and those with more belly fat were more likely to see the scarring get worse over a year. The drug tesamorelin was tested, but the abstract only reports on the placebo group’s outcomes, so it doesn’t prove the drug helps.

Utility 2
pubmed Apr 30, 2011

Relationship of adiponectin to endogenous GH pulse secretion parameters in response to stimulation with a growth hormone releasing factor.

Makimura. H H; Stanley. T L TL; Chen. C Y CY; Branch. K L KL; Grinspoon. S K SK

In a small study of 13 men, boosting the body's own growth hormone with tesamorelin for two weeks raised GH and IGF‑1 levels but did not change either total or high‑molecular‑weight adiponectin, a hormone linked to insulin sensitivity. While GH pulses were strongly linked to baseline adiponectin levels, short‑term GH stimulation didn't move the needle.

Utility 1
pubmed May 17, 2022

Approach to the Patient With Lipodystrophy.

Fourman. Lindsay T LT; Grinspoon. Steven K SK

Lipodystrophy is a rare condition where people have little or no body fat, which messes up metabolism, causing insulin resistance, high triglycerides, and fat building up in the wrong places. It’s probably more common than we think, so doctors should look for it and check for heart, metabolic, and other health problems. Studying this extreme lack of fat can also teach us about regular obesity.

Utility 1
pubmed Dec 31, 2019

Peptide Ligation at High Dilution via Reductive Diselenide-Selenoester Ligation.

Chisholm. Timothy S TS; Kulkarni. Sameer S SS; Hossain. Khondker R KR; Cornelius. Flemming F; Clarke...

Scientists developed a new chemistry trick that lets them stitch together peptide pieces even when they’re in very tiny amounts and hard to dissolve. Using this trick, they made the drug tesamorelin and some fat‑attached versions of a membrane protein, showing the method works but it doesn’t change how the drug is used in people.